Lead investigator Suresh Ramalingam discusses the practice-changing results of the FLAURA study pitting osimertinib against gefitinib or erlotinib in the first-line advanced NSCLC setting.
15-09-2017 | ESMO 2017 | Video
15-09-2017 | ESMO 2017 | Video
Lead investigator Suresh Ramalingam discusses the practice-changing results of the FLAURA study pitting osimertinib against gefitinib or erlotinib in the first-line advanced NSCLC setting.